GLP-1 side effects and safety basics

GLP-1 receptor agonists are effective medications, but they carry real side effects and serious safety warnings that patients need to understand before starting treatment. This guide covers incidence rates from clinical trials, the dose-escalation schedules designed to manage tolerability, boxed warnings from prescribing information, and the separate safety considerations around compounded products.

Common side effects: incidence rates from clinical trials

Gastrointestinal side effects are the most frequently reported adverse events in GLP-1 clinical trials. They typically emerge during dose escalation and improve as the body adjusts over weeks to months. The following rates come from the STEP (semaglutide) and SURMOUNT (tirzepatide) pivotal trial programs:

• Nausea: 44% with semaglutide 2.4 mg (STEP 1) versus 16% placebo; 24-33% with tirzepatide across doses (SURMOUNT-1) versus 9% placebo. Nausea is the single most common reason patients cite for considering discontinuation.

• Diarrhea: 30% with semaglutide versus 16% placebo; 19-25% with tirzepatide versus 7% placebo.

• Vomiting: 24% with semaglutide versus 6% placebo; 9-13% with tirzepatide versus 2% placebo.

• Constipation: 24% with semaglutide versus 11% placebo; 17-21% with tirzepatide versus 5% placebo.

• Abdominal pain: 11% with semaglutide versus 6% placebo; similar rates with tirzepatide.

• Injection site reactions: 3-5% across products, typically mild and transient.

These rates represent the overall trial population. Individual experience varies — some patients tolerate escalation with minimal issues, while others experience persistent symptoms that require dose reduction, slower titration, or discontinuation.

Dose-escalation schedules: why slow titration matters

GLP-1 medications use gradual dose escalation specifically to reduce GI side effect severity. Skipping steps or accelerating the schedule increases the risk of nausea, vomiting, and other GI distress.

For semaglutide, the standard escalation takes 16 weeks to reach the 2.4 mg maintenance dose. For tirzepatide, reaching the maximum 15 mg dose takes at least 20 weeks. Clinicians can extend any step by an additional 4 weeks if a patient is not tolerating the current dose.

Serious warnings and safety signals

Beyond common GI side effects, GLP-1 receptor agonists carry several clinically important warnings in their prescribing information:

Boxed warning: thyroid C-cell tumors

Both semaglutide and tirzepatide carry a boxed warning (the FDA's most serious warning category) regarding thyroid C-cell tumors. In rodent studies, GLP-1 RAs caused dose-dependent and treatment-duration-dependent increases in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether these drugs cause thyroid C-cell tumors, including MTC, in humans. The drugs are contraindicated in patients with a personal or family history of MTC or in patients with MEN 2.

Pancreatitis

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been reported in patients treated with GLP-1 RAs. Patients should be instructed to report severe, persistent abdominal pain that may radiate to the back, with or without vomiting. If pancreatitis is suspected, the drug should be discontinued promptly.

Gallbladder disease

Clinical trials showed higher rates of cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) in patients on GLP-1 RAs versus placebo. Rapid weight loss — regardless of mechanism — is a known risk factor for gallstone formation. Patients should be counseled about symptoms (right upper quadrant pain, fever, jaundice).

Acute kidney injury

Reports of acute kidney injury and worsening of chronic renal failure have been reported in patients treated with GLP-1 RAs. The mechanism is typically dehydration from GI side effects (persistent vomiting, diarrhea). Patients with renal impairment should be monitored, and hydration should be emphasized.

Suicidal ideation

The FDA has investigated reports of suicidal ideation and behavior in patients using GLP-1 RAs. While a causal relationship has not been established, the labels now recommend monitoring for depression, suicidal thoughts, or unusual changes in mood or behavior. Patients with a history of suicidal behavior should discuss this with their prescriber before starting treatment.

Weight regain after discontinuation

An important safety-adjacent consideration is what happens when patients stop taking GLP-1 medication. Data from the STEP 1 trial extension (published 2022) showed that participants who discontinued semaglutide after 68 weeks regained approximately two-thirds of their lost weight within the following year — net weight loss fell from 17.3% to just 5.6% one year after stopping. The SURMOUNT-4 trial showed more than 50% of weight loss rebounded within 52 weeks of stopping tirzepatide. A 2025 meta-analysis in eClinicalMedicine found pooled mean regain of 5.63 kg after discontinuation across GLP-1 RAs.

Real-world data paints a somewhat more optimistic picture: an Epic Research analysis found that 56.1% of semaglutide users maintained or improved their weight loss 2 years after discontinuation. Still, the clinical consensus is clear — obesity is a chronic condition, and GLP-1 medications are best understood as ongoing treatments similar to blood pressure or cholesterol medication. Patients should understand this before starting treatment and discuss long-term planning with their provider.

Compounded product safety concerns

Compounded GLP-1 products carry additional safety risks beyond those associated with FDA-approved formulations:

• Potency variability: compounded products are not subject to the same manufacturing standards as FDA-approved drugs. Testing by independent labs has found significant potency variations between batches.

• Sterility: injectable medications must be sterile. The FDA has cited compounding pharmacies for sterility failures and inadequate quality controls.

• Salt form differences: some compounding pharmacies use semaglutide sodium or semaglutide acetate rather than the semaglutide base used in Wegovy. These are different chemical entities that have not been independently evaluated for safety and efficacy.

• Storage and stability: compounded products may have different storage requirements and shorter shelf lives. Improper temperature control during shipping or storage can degrade the active ingredient.

Questions to ask your provider about safety

• What is the protocol if I cannot tolerate a dose increase? Can the escalation schedule be extended?

• How do I reach a clinician between scheduled visits if I experience concerning symptoms?

• What are the specific signs that I should seek emergency care versus scheduling a follow-up?

• If I need to discontinue, what is the recommended tapering protocol and what should I expect regarding weight regain?

• For compounded products: which pharmacy compounds the medication, are they 503A or 503B, and do they publish third-party potency and sterility testing results?